Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose pharmacokinetics of brexpiprazole long-acting injectable in schizophrenia
jRCT2061210051Phase 1Suspended
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of brexpiprazole in schizophrenia (4 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Plasma concentrations of brexpiprazole. Started Nov 2021; status: suspended.
02
Drugs
brexpiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2061210051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210051.